 Mary Demoruelle
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 58 | 2024 | 1002 | 10.300 |
Why?
| | Autoantibodies | 34 | 2023 | 1345 | 4.800 |
Why?
| | Anti-Citrullinated Protein Antibodies | 17 | 2023 | 90 | 4.640 |
Why?
| | Lung Diseases, Interstitial | 10 | 2024 | 507 | 2.780 |
Why?
| | Immunoglobulin A | 10 | 2023 | 166 | 2.520 |
Why?
| | Extracellular Traps | 4 | 2023 | 40 | 2.330 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2023 | 505 | 2.230 |
Why?
| | Connective Tissue Diseases | 4 | 2023 | 71 | 2.220 |
Why?
| | Peptides, Cyclic | 13 | 2023 | 253 | 2.080 |
Why?
| | Immunity, Mucosal | 4 | 2020 | 84 | 1.840 |
Why?
| | Sputum | 4 | 2021 | 285 | 1.800 |
Why?
| | Autoimmunity | 10 | 2021 | 813 | 1.710 |
Why?
| | Rheumatoid Factor | 11 | 2023 | 157 | 0.960 |
Why?
| | Antiphospholipid Syndrome | 1 | 2023 | 26 | 0.870 |
Why?
| | Citrullination | 3 | 2020 | 12 | 0.830 |
Why?
| | Bronchial Diseases | 2 | 2013 | 38 | 0.820 |
Why?
| | Citrulline | 3 | 2020 | 40 | 0.740 |
Why?
| | Microbiota | 3 | 2021 | 647 | 0.740 |
Why?
| | Inflammation | 5 | 2022 | 2477 | 0.690 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2022 | 219 | 0.660 |
Why?
| | Humans | 65 | 2024 | 114623 | 0.650 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2023 | 797 | 0.610 |
Why?
| | Autoantigens | 4 | 2022 | 396 | 0.600 |
Why?
| | Lung | 8 | 2023 | 3558 | 0.590 |
Why?
| | Pedigree | 2 | 2020 | 460 | 0.560 |
Why?
| | Lung Diseases | 2 | 2013 | 701 | 0.520 |
Why?
| | Pneumonia | 1 | 2020 | 567 | 0.470 |
Why?
| | Middle Aged | 28 | 2022 | 26719 | 0.420 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 75 | 0.400 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 106 | 0.390 |
Why?
| | Arthritis | 1 | 2012 | 109 | 0.380 |
Why?
| | Respiration Disorders | 2 | 2022 | 69 | 0.380 |
Why?
| | Aged | 18 | 2022 | 19061 | 0.380 |
Why?
| | Risk Factors | 15 | 2022 | 8628 | 0.380 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 382 | 0.370 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.370 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 122 | 0.370 |
Why?
| | Female | 34 | 2022 | 59466 | 0.360 |
Why?
| | Male | 32 | 2022 | 55554 | 0.360 |
Why?
| | Antirheumatic Agents | 1 | 2012 | 255 | 0.340 |
Why?
| | Adult | 23 | 2022 | 30528 | 0.330 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 290 | 0.330 |
Why?
| | Case-Control Studies | 8 | 2021 | 3003 | 0.320 |
Why?
| | Histones | 3 | 2021 | 535 | 0.290 |
Why?
| | Neutrophils | 2 | 2023 | 1176 | 0.280 |
Why?
| | Epitopes | 5 | 2023 | 435 | 0.270 |
Why?
| | Prospective Studies | 11 | 2022 | 6217 | 0.270 |
Why?
| | Disease Progression | 7 | 2021 | 2380 | 0.260 |
Why?
| | Intestines | 2 | 2021 | 326 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2084 | 0.230 |
Why?
| | Adenylate Kinase | 1 | 2023 | 26 | 0.220 |
Why?
| | Antibody Formation | 3 | 2022 | 266 | 0.220 |
Why?
| | Incidence | 5 | 2021 | 2311 | 0.210 |
Why?
| | Dysbiosis | 2 | 2020 | 146 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 72 | 0.180 |
Why?
| | Hydrolases | 1 | 2021 | 51 | 0.180 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 84 | 0.180 |
Why?
| | Neutrophil Activation | 1 | 2021 | 94 | 0.180 |
Why?
| | Vimentin | 1 | 2020 | 58 | 0.180 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.180 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.180 |
Why?
| | Early Diagnosis | 3 | 2022 | 217 | 0.180 |
Why?
| | Milk Proteins | 1 | 2020 | 36 | 0.170 |
Why?
| | Mucin-5B | 1 | 2022 | 183 | 0.170 |
Why?
| | Bacteriophages | 1 | 2021 | 75 | 0.170 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 167 | 0.170 |
Why?
| | Muramidase | 1 | 2020 | 72 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 180 | 0.170 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 81 | 0.170 |
Why?
| | Acetaldehyde | 1 | 2019 | 15 | 0.170 |
Why?
| | Malondialdehyde | 1 | 2019 | 28 | 0.170 |
Why?
| | Mammary Glands, Animal | 1 | 2020 | 117 | 0.160 |
Why?
| | Occupational Exposure | 1 | 2022 | 255 | 0.160 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 119 | 0.160 |
Why?
| | Biomarkers | 5 | 2021 | 3408 | 0.160 |
Why?
| | Family Characteristics | 1 | 2020 | 151 | 0.160 |
Why?
| | Immunoglobulin G | 5 | 2023 | 770 | 0.160 |
Why?
| | Nuclear Family | 1 | 2019 | 49 | 0.160 |
Why?
| | Lactation | 1 | 2020 | 149 | 0.160 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 130 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 502 | 0.150 |
Why?
| | Mucous Membrane | 1 | 2018 | 108 | 0.150 |
Why?
| | Prevalence | 2 | 2022 | 2249 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2016 | 46 | 0.140 |
Why?
| | Plasma Cells | 1 | 2016 | 56 | 0.130 |
Why?
| | Complement System Proteins | 1 | 2019 | 282 | 0.130 |
Why?
| | Peptides | 1 | 2021 | 848 | 0.130 |
Why?
| | Mitochondria | 1 | 2021 | 747 | 0.130 |
Why?
| | Animals | 5 | 2023 | 31694 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 4405 | 0.120 |
Why?
| | Molecular Mimicry | 1 | 2014 | 35 | 0.120 |
Why?
| | Young Adult | 3 | 2021 | 10455 | 0.120 |
Why?
| | Mice | 4 | 2023 | 14860 | 0.120 |
Why?
| | Immunoglobulin M | 3 | 2022 | 246 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 493 | 0.110 |
Why?
| | Mass Screening | 1 | 2020 | 1004 | 0.110 |
Why?
| | Mouth Mucosa | 1 | 2014 | 79 | 0.110 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 7 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2020 | 944 | 0.100 |
Why?
| | Prognosis | 2 | 2021 | 3328 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1691 | 0.100 |
Why?
| | Population Surveillance | 1 | 2015 | 392 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2013 | 284 | 0.100 |
Why?
| | Remission Induction | 1 | 2012 | 233 | 0.100 |
Why?
| | Arthrography | 1 | 2011 | 22 | 0.100 |
Why?
| | Age Factors | 1 | 2019 | 2894 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2022 | 9084 | 0.100 |
Why?
| | Blood Pressure | 1 | 2017 | 1538 | 0.090 |
Why?
| | Time-to-Treatment | 1 | 2012 | 147 | 0.090 |
Why?
| | Joints | 1 | 2011 | 84 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1075 | 0.090 |
Why?
| | Time Factors | 3 | 2020 | 6112 | 0.090 |
Why?
| | Air Pollution | 1 | 2013 | 169 | 0.090 |
Why?
| | Disease Susceptibility | 2 | 2021 | 316 | 0.080 |
Why?
| | Vital Capacity | 2 | 2022 | 255 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1342 | 0.080 |
Why?
| | Organ Specificity | 2 | 2019 | 268 | 0.080 |
Why?
| | Cohort Studies | 3 | 2022 | 4894 | 0.070 |
Why?
| | Family | 2 | 2021 | 589 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1139 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1430 | 0.060 |
Why?
| | Smoking | 2 | 2024 | 1380 | 0.060 |
Why?
| | Telomere Shortening | 1 | 2024 | 17 | 0.060 |
Why?
| | Azathioprine | 1 | 2022 | 49 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.050 |
Why?
| | Rituximab | 1 | 2022 | 150 | 0.050 |
Why?
| | Telomere | 1 | 2024 | 202 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 125 | 0.050 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 40 | 0.050 |
Why?
| | Cytokines | 2 | 2020 | 1840 | 0.050 |
Why?
| | Arthralgia | 1 | 2021 | 46 | 0.050 |
Why?
| | Vitamins | 1 | 2022 | 151 | 0.050 |
Why?
| | Genetic Markers | 1 | 2022 | 320 | 0.050 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 69 | 0.050 |
Why?
| | Synovial Fluid | 1 | 2020 | 56 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 237 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 124 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 397 | 0.040 |
Why?
| | Prolactin | 1 | 2020 | 96 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 274 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 176 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4099 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 211 | 0.040 |
Why?
| | Methotrexate | 1 | 2020 | 226 | 0.040 |
Why?
| | Vitamin D | 1 | 2022 | 341 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 370 | 0.040 |
Why?
| | Arginine | 1 | 2020 | 238 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2022 | 646 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 520 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 531 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 98 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4411 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 379 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 477 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 430 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 399 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 477 | 0.040 |
Why?
| | Phylogeny | 1 | 2021 | 789 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2021 | 676 | 0.040 |
Why?
| | Environment | 1 | 2019 | 332 | 0.040 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 6 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 10 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 14 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 63 | 0.030 |
Why?
| | Proteome | 1 | 2020 | 339 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 340 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 58 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 789 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1262 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 12542 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 87 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 695 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2015 | 60 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 725 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 413 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 953 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1421 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1211 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 142 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 836 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 475 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2387 | 0.030 |
Why?
| | Risk | 1 | 2016 | 812 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 723 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 439 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2537 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 811 | 0.030 |
Why?
| | United States | 2 | 2022 | 12176 | 0.030 |
Why?
| | Geographic Information Systems | 1 | 2013 | 37 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2552 | 0.030 |
Why?
| | Cell Membrane | 1 | 2016 | 680 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2020 | 3881 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2016 | 460 | 0.030 |
Why?
| | Body Mass Index | 1 | 2019 | 1956 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 1879 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2967 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1644 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3344 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 185 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 591 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 254 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 1644 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 362 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2319 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2279 | 0.020 |
Why?
| | Adolescent | 1 | 2021 | 17831 | 0.010 |
Why?
|
|
Demoruelle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|